THE SEVERITY OF DEPRESSIVE DISORDER AND THE RATIO OF PHARMACO-AND PSYCHOTHERAPY: THE RATIONALE FOR MEDICAL CHOICE



Cite item

Full Text

Abstract

The aim of the work was to review the literature on the problem of assessing the severity of depression in the light of changes in the systematization of mental disorders. The relevance of the correct assessment of mental disorders on the example of depressive disorder is substantiated. New approaches to determining the severity of disorders in DSM-V are presented, their variability is noted. The influence of the severity of depression on the choice of therapy, preference for psychopharmacotherapy or psychotherapy is analyzed. It is concluded that the prospect of assessing the severity of depression on the basis of dimensions.

About the authors

Nataliia Nikolaevna Petrova

Author for correspondence.
Email: petrova_nn@mail.ru

References

  1. Zimmerman М., Morgan Т.А., Stanton К. Тяжесть психических расстройств. Всемирная психиатрия. 2018; 03: 253-269.
  2. Guo T., Xiang Y-T., Xiao L. et al. Measurement-based care versus standard care for major depression: a randomized controlled trial with blind raters. Am J Psychiatry. 2015;172:1004-13.
  3. Bower P., Kontopantelis E., Sutton A. et al. Influence of initial severity of depression on effectiveness of low intensity interventions: meta-analysis of individual patient data. BMJ 2013; 346: f540. doi: 10.1136/bmj.f540.
  4. Grammer G.G., Kuhle A.R., Clark C.C. et al. Severity of depression predicts remission rates using transcranial magnetic stimulation. Front Psychiatry 2015;6:114. doi: 10.3389/fpsyt.2015.00114.
  5. Lisanby S.H., Husain M.M., Rosenquist P.B. et al. Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacology. 2009; 34:.522-34.
  6. Friedman E.S., Davis L.L., Zisook S. et al. Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial. Eur Neuropsychopharmacol. 2012; 22: 183-99.
  7. Kennedy S., Andersen H., Lam R. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine SR: a meta-analysis. J Psychiatry Neurosci. 2006; 31: 122-31.
  8. Wiles N.J., Mulligan J., Peters T.J. et al. Severity of depression and response to antidepressants: GENPOD randomised controlled trial. Br J Psychiatry. 2011;.200:.130-6.
  9. Khan A., Sambunaris A., Edwards J. et al. Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression. Int Clin Psychopharmacol. 2014; 29: 86-92.
  10. Mosca D., Zhang M., Prieto R. et al. Efficacy of desvenlafaxine compared with placebo in major depressive disorder patients by age group and severity of depression at baseline. J Clin Psychopharmacol. 2017; 37: 182-92.
  11. Driessen E., Cuijpers P., Hollon S.D. et al. Does pretreatment severity moderate the efficacy of psychological treatment of adult outpatient depression? A meta-analysis. J Consult Clin Psychol. 2010; 78: 668-80.
  12. Furukawa T.A., Weitz E.S., Tanaka S. et al. Initial severity of depression and efficacy of cognitive-behavioural therapy: individual-participant data metaanalysis of pill-placebo-controlled trials. Br J Psychiatry. 2017; 210: 190-6.
  13. Henkel V., Seemuller F., Obermeier M. et al. Relationship between baseline severity of depression and antidepressant treatment outcome. Pharmacopsychiatry. 2011; 44: 27-32.
  14. Madhoo M., Levine S.Z. Initial severity effects on residual symptoms in response and remission: a STAR*D study during and after failed citalopram treatment. J Clin Psychopharmacol. 2015; 35: 450-3.
  15. Менделевич В.Д. Доказательная психотерапия: между возможным и необходимым. Неврологический вестник. 2019; 2: 4—11. [Mendelevich V. D. Evidence-based psychotherapy: between the possible and the necessary. Nevrologicheskij vestnik. 2019; 2: 4—11. (In Russ.)]]
  16. Cuijpers P., van Straten A., van Oppen P. et al. Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies. J Clin Psychiatry. 2008; 69:1675-85.
  17. Weitz E.S., Hollon S.D., Twisk J. et al. Baseline depression severity as moderator of depression outcomes between cognitive behavioral therapy vs. pharmacotherapy: an individual patient data meta-analysis. JAMA Psychiatry. 2015;.72:1102-9.
  18. Fournier J.C., DeRubeis R.J., Hollon S.D. et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010; 303:47-53.
  19. Khan A., Leventhal R.M., Khan S.R. et al. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol. 2002; 22: 40-5.
  20. Kirsch I., Deacon B.J., Huedo-Medina T.B. et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5: 260-8.
  21. Gibbons R., Hur K., Brown C. et al. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012; 69: 572-9.
  22. Mosca D., Zhang M., Prieto R. et al. Efficacy of desvenlafaxine compared with placebo in major depressive disorder patients by age group and severity of depression at baseline. J Clin Psychopharmacol. 2017; 37: 182-92.
  23. Rabinowitz J., Werbeloff N., Mandel F.S. et al. Initial depression severity and response to antidepressants vs. placebo: patient-level data analysis from 34 randomised controlled trials. Br J Psychiatry. 2016; 209: 427-8.
  24. Turner E.H., Matthews A.M., Linardatos E. et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008; 358: 252-60.
  25. https://www.who.int/mental_health/mhgap/evidence/depression/q1/ru/
  26. Hollon S. D., Fawcett J. Combined medication and psychotherapy. In G. Gabbard (Ed.), Treatments of psychiatric disorders (2nd ed., pp. 1221-1236). Washington, DC: American Psychiatric Press. 1995; 1247p.
  27. Keller M.B., McCullough J.P. Jr. Klein D.N. et al. A comparison of nefazodone, the cognitive behavioral analysis system of psychotherapy, and their combination for the treatment of chronic depression. New England Journal of Medicine. 2000; 342: 1462–1470.
  28. Kotov R., Krueger R.F., Watson D. et al. The Hierarchical Taxonomy of Psychopathology (HiTOP): a dimensional alternative to traditional nosologies. J Abnorm Psychol. 2017; 126: 454-77.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Petrova N.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 75562 от 12 апреля 2019 года.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies